Bridge Investment Fund

Bucketfeet is a direct-to-consumer shoe brand based in Chicago, Illinois, founded in 2011 by Raaja Nemani and Aaron Firestein. The company collaborates with a global community of artists to design limited-edition shoes, allowing each artist to create unique shoe designs that are printed on sneakers once ordered online. This responsive commerce model enables Bucketfeet to disrupt traditional manufacturing cycles by letting the community select styles they’d like to purchase and wear, thereby informing demand. In addition to shoes, Bucketfeet offers tees, hoodies, and socks, all available for purchase through its online platform. The company aims to spark meaningful conversations and create a brighter world by empowering artists to share their stories and perspectives using art on footwear as their canvas.

EarlySense Ltd. is a developer of advanced patient monitoring systems tailored for hospitals, healthcare systems, integrated delivery networks, and rehabilitation centers. Founded in 2004 and based in Ramat Gan, Israel, with additional offices in Woburn, Massachusetts, the company specializes in signal-processing technology that enhances patient safety and facilitates early detection of health deterioration. Its flagship product, the EarlySense System, offers continuous monitoring of heart rate, respiratory rate, and patient motion, allowing clinical teams to manage risks such as falls and pressure ulcers. Additionally, the Central Display Station enables nursing staff to supervise patients effectively, while the contact-free consumer health monitor, known as LIVE, provides users and caregivers with insights into heart health, breathing cycles, and sleep quality. The company's offerings, including EarlySense Live, cater to a variety of healthcare environments and are distributed in Israel, the United States, and Australia. EarlySense has established a strategic partnership with Welch Allyn to further enhance its product capabilities.

EarlySense Ltd. is a developer of advanced patient monitoring systems tailored for hospitals, healthcare systems, integrated delivery networks, and rehabilitation centers. Founded in 2004 and based in Ramat Gan, Israel, with additional offices in Woburn, Massachusetts, the company specializes in signal-processing technology that enhances patient safety and facilitates early detection of health deterioration. Its flagship product, the EarlySense System, offers continuous monitoring of heart rate, respiratory rate, and patient motion, allowing clinical teams to manage risks such as falls and pressure ulcers. Additionally, the Central Display Station enables nursing staff to supervise patients effectively, while the contact-free consumer health monitor, known as LIVE, provides users and caregivers with insights into heart health, breathing cycles, and sleep quality. The company's offerings, including EarlySense Live, cater to a variety of healthcare environments and are distributed in Israel, the United States, and Australia. EarlySense has established a strategic partnership with Welch Allyn to further enhance its product capabilities.

Navotek Medical develops real-time innovative tracking and navigation solutions for medical applications. The first application is in the oncology field, providing tumor localization and tracking for optimal radiation therapy. Navotek’s solution will allow for safer and more effective treatment, improving the chances of tumor eradication and decreasing the rate of complications. In addition, it will potentially improve the efficiency of the treatment procedure by shortening individual sessions as well as entire treatment courses. This will increase the radiation rooms’ throughput which will translate into increased earnings for the hospital.

CritiSense, Ltd., founded in 2004 and based in Giv'at Shmu'el, Israel, develops medical devices for real-time monitoring of patients' metabolic states. Its flagship product, CritiView, is a monitoring system that provides continuous, real-time information via four physiological parameters sensed at the tissue level. This data reflects the patient’s systemic metabolic state and helps identify imbalances in tissue and body vitality. The device is used by surgeons, anesthesiologists, and caregivers in intensive care units to enhance surgical outcomes and patient care. CritiView monitors mitochondrial function, microcirculatory blood flow, and oxygen saturation using an optical sensor, offering valuable insights into a patient's physiological status during critical procedures or intensive care.